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Is the nitric oxide system involved in genetic hypertension in Dahl rats?
To address this issue, a series of genetic tests were carried out. Linkage
studies showed that the inducible nitric oxide synthase (Nos2) locus
cosegregated with blood pressure in three F2 populations originated from
crosses of Dahl salt-sensitive (S) rats with rats of various normotensive
strains. However, the brain nitric oxidase synthase (Nos1) and endothelial
nitric oxide synthase (Nos3) loci did not cosegregate with blood pressure
in five F2 populations. Thus, only Nos2, but not Nos1 and Nos3, was
considered as a candidate gene for being a quantitative trait locus (QTL)
for blood pressure in the S rat. To further test this hypothesis, congenic
strains were constructed by substituting regions on Chromosome 10 of the
S rat with the homologous regions of the Milan normotensive (MNS) rat.
Results showed that the chromosome region including Nos2 did not
contain a blood pressure QTL. In consequence, Nos2 per se is not
supported as a candidate QTL capable of causing a blood pressure
difference between the S and MNS rats. Nevertheless, the nitric oxide
system appears to be involved secondarily in the regulation of blood
pressure in the S rat, as evidenced by physiological data.
It is well known that blood pressure is a quantitatively measured
and polygenic trait determined by multiple genes. In studying
most common human genetic hypertension controlled by poly-
genic determinants, difficulties often arise in the attempt to
dissect the defective genetic elements causing hypertension, be-
cause of the heterogeneity of the disorder both in definition and
severity in human populations, and because of the impossibility of
controlling breeding and the environment. Experimental models
using inbred hypertensive animals have become complementary
and, to some extent, alternative to a direct study of human genetic
hypertension. A discussion on how animal models might facilitate
discovery of hypertension genes in humans is presented in [1].
THE RAT AS AN EXPERIMENTAL GENETIC MODEL
Rat hypertensive models have contributed greatly to our un-
derstanding of genetic hypertension. Because blood pressure-
raising alleles of genes have been enriched in these rats during
selection, more so than normotensive rats, these hypertensive
models have been employed to localize the quantitative trait locus
(QTL) for blood pressure. A blood pressure QTL in the rat is
defined as a locus genetically determining a difference in blood
pressure between two contrasting rat strains, usually a hyperten-
sive and a normotensive strain. The abbreviation of QTL is used
for both singular and plural QTL.
In localizing and finally identifying a blood pressure QTL, an
overall strategy has been gradually emerging that combines the
tools of molecular genetics with judiciously designed crosses of
appropriate rat strains. This strategy can be characterized by a
four-step sequential approach: (i) map blood pressure QTL onto
chromosome regions by linkage analysis; (ii) establish the chro-
mosome regions containing blood pressure QTL using congenic
strains; (iii) narrow down these regions to 1 to 2 centiMorgans
(cM) in size using congenic substrains involving progressively
smaller and smaller chromosome substitutions; (iv) eventually
identify blood pressure QTL by either positional cloning and/or
candidate gene cloning.
The basic approach used in the initial localization of a blood
pressure QTL is linkage analysis in a population. The underlying
principle of linkage analysis is that differing alleles of a blood
pressure QTL have to be linked to blood pressure variations in
such a segregating population [2]. However, the conclusion from
linkage analyses is solely based on probability, not on certainty,
and consequently, is prone to produce false positives [3–5]. To
prove that the chromosome region truly contains a blood pressure
QTL, a more definitive and stringent genetic test is required. The
genetic test of choice to study blood pressure QTL in an animal
model is the use of congenic strains.
The use of congenic strains was originally conceived by Snell [6]
in studying histocompatibility phenomena in the mouse, and has
since been widely used in studying inherited traits [7]. Congenic
strains can be used to establish the existence of a blood pressure
QTL in a broad, but specific, chromosome region implicated by
linkage analysis. Table 1 summarizes the blood pressure QTL
mapped thus far in the Dahl salt sensitive (S) rat. Once a blood
pressure QTL has been mapped with certainty onto a chromo-
some region, the next task is to narrow the chromosome region
containing the QTL to a 1 to 2 cM segment for its ultimate
identification at the molecular level [4].
The next step after fine mapping is to pinpoint the exact
location of the QTL on the chromosomes. There are two com-
monly used approaches to achieve this goal, positional cloning and
candidate gene cloning. Without knowing the physiological func-
tions of a blood pressure QTL, positional cloning is the preferred
approach [27]. An alternative approach to the exhaustive and
laborious method of positional cloning in identifying a blood
pressure QTL is the analysis of candidate genes that fall into the
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candidate chromosomal intervals [27]. The candidate gene ap-
proach relies on the assumption that a QTL has to perform
functions that are physiologically relevant to the trait under
investigation, such as blood pressure. Through many decades of
research, there has been a wealth of knowledge accumulated on
the physiological functions of molecules involved in blood pres-
sure regulation [28]. Genes coding for these molecules can be
candidate genes for blood pressure QTL if they are present in 1 to
2 cM chromosome regions to which blood pressure QTL have
been localized. Among candidate genes, those involved in the
nitric oxide system are noteworthy.
THE NITRIC OXIDE SYSTEM
Among its alleged physiological functions, such as aiding in
cytotoxicity mediated by macrophages [29] and serving as a
neurotransmitter [30], nitric oxide (NO) is thought to account for
the activity of an endothelium-derived relaxing factor originally
described by Furchgott and Zawadzki [31]. Three types of en-
zymes known as nitric oxide synthase (NOS) that are primarily
responsible for NO production have been identified. Two types of
NOS, designated as NOS1 or “brain” NOS, and NOS3 or
“endothelial” NOS, are “constitutively” expressed, and are Ca21
and calmodulin-dependent. The remaining type designated as
NOS2 is “inducible” and is Ca21-independent [29]. In this article,
NOS in capital letters represents an enzyme, Nos in italics
represents a gene or a locus in the rat or mouse, and NOS in
capital italics represents a human gene or locus.
Physiological evidence implicating a flaw in the L-arginine-
nitric oxide pathway in the Dahl salt-sensitive rat
Dahl, Heine and Tassinari [32] demonstrated that salt intake
profoundly influences arterial blood pressure of the S rat. In
studying both young S and young Dahl salt-resistant (R) rats
raised on a high salt (8% NaCl) diet, Chen and Sanders [33]
showed that L-arginine, the substrate for NOS, caused a decrease
in blood pressure in the S rat, but not in the R rat when infused
intravenously. NG-monomethyl-L-arginine (L-NMMA), a com-
petitive inhibitor of NOS, raised blood pressure more in the R rat
than in the S rat. L-arginine did not lower blood pressure in the S
rat fed on a low salt (0.3% NaCl) diet. Their results suggested
that: (a) NOS(s) is likely involved in the regulation of blood
pressure in the Dahl rats fed on a high salt diet; and (b) the S rat
may be defective in raising the activity of NOS compared to the R
rat in response to a high salt diet.
The S rat appeared to be unique among hypertensive rat
models in utilizing the nitric oxide system because intravenous
injection of L-arginine had no effect on blood pressure in the
spontaneously hypertensive (SHR) rat [33]. Furthermore, a com-
parison of NO release and hypotensive effects in response to a
bolus injection of acetylcholine, a stimulator of NO production,
showed that there was no difference between the SHR rat and its
regularly-used normotensive “control” Wistar Kyoto (WKY) rat
[34]. L-NMMA increased blood pressure similarly in both SHR
and WKY [34]. Despite reports suggesting a role played by NO
[35], it remains to be determined whether NO is important in the
pathogenesis of hypertension in SHR.
Potential physiological mechanisms for hypertension in the
Dahl salt-sensitive rat due to a shortage of nitric oxide
It is known that several organ systems, including cardiovascular,
nervous, renal systems as well as humoral and endocrine systems,
are involved in hypertension of the S rat [36]. An insufficient
production of NO in the cardiovascular system has been impli-
cated in the pathogenesis of the S rat. Large arteries [37] and
arterioles [38] of the S rat fed on high salt manifested an impaired
and/or decreased NO synthesis or release.
Among these systems, however, the renal system appears to be
predominant. Dahl and Heine [39] showed that the replacement
of a kidney of the R rat with a kidney of the S rat induced
hypertension, whereas replacement of a S kidney with a R kidney
lowered blood pressure. Therefore, kidneys of the S rat are
hypertensinogenic. Kidneys of the S rat per se are important in
regulating blood pressure of the S rat independently of other
systems, such as the cardiovascular, nervous, and humoral sys-
tems. An obvious question to ask is “What are the defects in renal
function that render the S rat hypertensive?”
Roman [40] showed that at equivalent renal perfusion pressure,
outbred Dahl S rat could not excrete sodium as efficiently as
outbred R rats when challenged with a high-salt diet. Thus “the
pressure-diuresis and natriuresis relationships were blunted in the
Dahl S rats,” that is, a higher pressure is required to maintain
sodium balance. Based on the observation of Chen and Sanders
[33] that L-arginine could decrease the blood pressure of the
inbred Dahl S rat, Patel et al [41] found that a short-term or a
long-term administration of L-arginine was sufficient to normalize
the pressure-natriuresis relationship in outbred Dahl S rats fed a
high salt diet, but had no effect on the pressure-natriuresis
Table 1. Chromosome regions (rat chr) containing blood pressure QTL
localized in the S rat as reported in the literature
Rat
chr.
Contrasting
strain
Chromosome
region or
marker gene
Confirmed
in congenic
strains References
1 LEW SA (annoymous gene) [8]
1 LEW Genes for cytochrome
P450 enzymes
Yes [9, 10]
2 WKY, MNS D2N35/D2Mit Yes [11–13]
2 MNS Agtr 1b (angiotensin
receptor AT1B)
[12–14]
3 R Edn2 (endothelin 3) Yes [15, 16]
5 Lew Edn2 (endothelin 2) Yes [10, 17]
7 R 11b-hydroxylase* Yes [18–21]
10 LEW, MNS Mit-RR1023/
D10M11Mitl19
Yes [11, 22, 23]
13 R D13Mit3/R1032 Yes [24–26]
15 WKY Endrb (endothelin
receptor B)
[17]
17 LEW [17]
Contrasting strain refers to the normotensive rat strain involved in
localizing the quantative trait locus (QTL) on the chromosome. Abbrevi-
ations are: S, Dahl salt-sensitive (SS/Jr) strain; LEW, Lewis strain; WKY,
Wistar-Kyoto strain; MNS, Milan normotensive strain; and R, the Dahl
salt-resistant (SR/Jr) strain. Candidate genes refer to genes whose prod-
ucts are known to influence blood pressure physiologically. A candidate
gene on each chromosome refers to the candidate gene close to the
predicted position of the QTL. (*) the candidate gene probably is the QTL
itself. On Chromosomes 1 and 2, two separate QTL have been detected.
The S alleles of the putative QTL have always been found to be the high
blood pressure allele at all the loci identified thus far.
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relationship in outbred R rats. The remedial effect of L-arginine
on the S rats could be prevented by an inhibitor of nitric oxide
synthase, L-NAME. Their findings thus led to the conclusion that
the S rats had a defect(s) in the L-arginine-NO synthesis pathway
that caused the abnormal pressure-natriuresis relationship in the
S rat.
There are indications that a lack of adequate NO in mediating
various renal mechanisms may be, at least partially, responsible
for the abnormal pressure-natriuresis relationship in the S rat. In
several studies, normalization in pressure-natriuresis relationship
due to an increase in sodium excretion in outbred S rats after
L-arginine intake was found to be associated with an increase in
glomerular filtration rate [41], and with an improvement in
transmitting renal perfusion pressure to renal interstitium [42].
There is also evidence that renal tubular reabsorption in the S rat
is abnormal and this abnormality may have some connection with
a lack of sufficient NO. Roman and Kaldunski [43] showed that
reabsorption of water and chloride (probably sodium as well) was
elevated in the loop of Henle in both inbred and outbred S rats.
This enhanced reabsorption might lead to a decrease in sodium
excretion and, thus, contribute to the rightward shift of the
pressure-natriuresis relationship in the S rat. The role of NO in
the renal reabsorption of sodium has not been demonstrated for
the S rat, and, at the present, can only be inferred from the results
revealed from studying other rat strains. Work done by Mattson et
al [44] in studying Sprague-Dawley rats showed that the inhibition
of NO production by the infusion of L-NAME into the renal
medullary interstitium in the kidney medulla paralleled an in-
crease in the renal medullary flow, probably accompanied by an
enhancement in the renal tubular sodium reabsorption, and a
decrease in sodium excretion.
Nitric oxide also appears to be involved in inhibiting the sodium
transport in cultured mouse collecting duct cells [45], possibly by
directly curbing Na1/K1-ATPase activity [46] or by affecting the
apical membrane channel [47]. By extrapolating from this obser-
vation, one might speculate that an insufficient amount of NO in
the S rat could fail to prevent the sodium transport through
principal cells of the collecting duct. Consequently, less sodium
could be excreted. Similar speculations could be extended to
include a possible involvement of the proximal tubule in sodium
reabsorption negatively controlled by NO [48]. Furthermore, NO
generated in macula densa of Sprague-Dawley rats was probably
involved in increasing vasodilation of the afferent arteriole and in
increasing glomerular capillary pressure [49]. Presumably, an
increase in these functions could facilitate the sodium excretion. A
deficit in the NO production in macula densa of the S rat could
not be ruled out.
Physiological evidence implicating a defect in a nitric oxide
synthase in the Dahl salt sensitive rat
Since nitric oxide synthases (NOS) are mainly responsible for
the NO-synthesis [30], NOSs became primary candidates for
having a defect(s) underlying the flawed L-arginine-NO synthetic
pathway in the S rat. Studies by Chen and Sanders [50] showed
that the L-arginine-induced decrease in blood pressure in the S rat
fed on a high salt diet could be prevented by infusion of
dexamethasone, a selective inhibitor for the expression of NOS2,
but not of NOS1 and NOS3 [51]. Thus, their work implied that
NOS2, rather than NOS1 or NOS3, was involved in pathogenesis
of hypertension in the S rat. Ishimitsu et al [52] found that a
cytokine, interleukin-2, which could induce transcription of Nos2
[53], attenuated the progression of hypertension accompanied by
an improvement in the renal dysfunction of outbred S rats. On the
other hand, Given et al [54] could not find the antihypertensive
effect of interleukin-2 on outbred S rats.
Need for a conventional genetic approach
Although a preponderance of evidence was gravitating toward
the presence of a defect(s) of a NOS enzyme in the S rat on the
basis of physiological data, it has been impossible to pinpoint, by
physiological approaches, the genetic mutation(s) in any one of
the three classes of NOS enzymes. The absence of absolutely
specific inhibitors capable of discriminating among NOS isoforms
has only exasperated this difficulty.
Since Dahl and associates [32] founded separate salt-sensitive
(S) and salt-resistant (R) strains, and especially after Rapp and
Dene [55] established inbred lines for each strain, investigators
have sought to unravel genetic defects that cause differences in
blood pressure between the S and R rats by means of comparing
dissimilarities manifested through their physiological and bio-
chemical traits. However, serious limitations of using this ap-
proach are apparent. First of all, there are countless genetic
differences between S and R. These differences have resulted
from chance fixation of contrasting alleles in the two strains, and
most of them have nothing to do with blood pressure differences
between S and R. Secondly, physiological and biochemical traits
are often displayed as a result of an interaction between multiple
genetic determinants and complex environmental influences. Dif-
ferences in physiological and biochemical characteristics associ-
ated with blood pressure between S and R do not usually reflect
the direct effects of genes. Thirdly, dissimilarities in physiological
and biochemical traits associated with blood pressure can either
result directly from causative differences in genes, or alternatively,
can be brought about as consequences caused by integrated
interactions of the entire physiological system.
Interpretations for the work done by Ikeda et al [56] and by
Chen and Sanders [50] brought these shortcomings into a sharp
focus. Of the three types of NOS enzymes examined in vitro, Ikeda
et al [56] detected a difference in enzymatic activity of the NOS1
between outbred Iwai S and R rats. They concluded that NOS1,
not NOS2 and NOS3, was involved in pathogenesis of hyperten-
sion in the S rat. In contrast, physiological studies by Chen and
Sanders [50] reached a different conclusion, which is that NOS2,
but not NOS1 and NOS3, was likely to be important.
Parenthetically, both conclusions have to be taken with caution.
The difference in NOS1 activity detected by Ikeda et al [56] could
be attributed to a differential regulation at any of the stages after
the transcription of the Nos1 gene [29], rather than be attributed
to a difference in the Nos1 gene per se between the S and R rats.
Besides, their results of in vitro assays do not necessarily reflect
the true status in vivo. L-arginine, also a substrate for arginase in
the urea cycle [57], may lower blood pressure of the S rat by a
totally unknown mechanism other than being the substrate for
NOS. Dexamethasone used by Chen and Sanders [50], although a
selective inhibitor for NOS2 (but not NOS1 and NOS3), is not a
specific inhibitor for NOS2 because it can also inhibit the produc-
tion of the vasodilator, atrial natriuretic peptide (ANP) [58] and it
can inhibit the induction of arginino-succinate synthase, an en-
zyme involved in regeneration of arginine from citrulline [59].
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Similar to NO [29], ANP is potentiated through activating intra-
cellular second messenger cGMP and exhibits natriuretic effects
mediated, among other mechanisms, by inhibiting sodium absorp-
tion through renal inner medullary ducts [60]. In consequence,
studies with dexamethasone merely highlighted a possible com-
plex interaction between various physiological systems and dis-
closed little of the genetic defect [2] in a Nos gene.
There are limitations and drawbacks applying the results of
physiological studies using outbred rats such as Sprague-Dawley,
Wistar or Brookhaven Dahl S rats to understand the defective
physiological mechanisms underlying the L-arginine-NO pathway
in the inbred S rat. First, outbred rats are genetically highly
heterogeneous. This genetic heterogeneity causes uncontrollable
variability in blood pressure among different rats from the same
strain. For example, a divergence in blood pressure due to a
varying genetic makeup was found among Wistar Kyoto (WKY)
rats purchased from various commercial sources [61] and among
WKY rats from the same source [62]. Even among the supposedly
inbred Dahl salt-sensitive (S) rats available from Harlan Sprague-
Dawley, recent reports indicated that they had been genetically
contaminated [63, 64]. Because of this problem, some S rats failed
to develop hypertension after being fed a high salt diet.
Second, on top of being handicapped by genetic heterogeneity,
variations in experimental conditions often lead to conflicting
results from studying outbred rats. For instance, in studying the
chronic inhibition of NOSs using Sprague-Dawley rats, Shultz and
Tolins [65] found that the inhibition of the NO synthesis by
L-NMMA led to a salt-induced hypertension associated with a
decrease in the sodium excretion, whereas Johnson and Freeman
[66] only observed an increase in blood pressure without signifi-
cantly affecting the sodium excretion in the rats treated with
L-NAME. In studying Wistar rats, Ferna´ndez-Rivas, Garcı´a-
Estan˜ and Vargas [67] found that an administration of L-NAME
elevated blood pressure of the rats, but did not cause an impair-
ment of their sodium excretion. Explanation for these conflicting
results can be due to one or any combinations of the following
reasons. (a) Because the compositions of the NO inhibitors used
in these experiments, that is, L-NMMA and L-NAME, are
different, their effects on renal functions could be changed due to,
for example, the degree of specificity on NOSs. (b) The routes of
injection of the inhibitors into the rats could potentially make a
difference. (c) Doses of the particular inhibitor used, especially
the amount of the NO inhibitor effective at the organ site, could
have an impact on the outcome of these experiments. (d) The
length of time between the start of NOS inhibitor treatment and
measurements of both blood pressure and sodium excretion could
potentially influence the outcome of the experiments.
Recently, gene “knock-out” experiments in the mouse showed
that the homozygous mice lacking the “neuronal” form of Nos
(that is, Nos1) had blood pressure similar to that of wild-type mice
[68]. Thus, the involvement of Nos1 in genetic hypertension is
unclear. The homozygous mice deficient in the “inducible” form
of Nos (that is, Nos2) did not show a drastic decrease in blood
pressure as wild-type mice did in response to the injection of
lypopolysaccharides (LPS) [69]. This result indicates Nos2 may
have a blood pressure-lowering effect. Whether the blood pres-
sure of the mice lacking Nos2 would be different from that of
wild-type mice without LPS induction remains to be determined.
Two other groups [70, 71] working with independent Nos2
“knock-outs” did not analyze blood pressure effects. In mice
missing the “endothelial” form of Nos (that is, Nos3), their blood
pressure was significantly higher than that of wild-type mice [72].
This result suggests that Nos3 also has a blood pressure-lowering
effect.
Nevertheless, the mouse models with these Nos gene “knock-
outs” could not be directly applied to the understanding of genetic
defects underlining a potentially flawed L-arginine-NO pathway
in the S rat. For one thing, the S rat possesses all three Nos genes,
which are intact, expressed and functional in, for instance, kidneys
[56, 73, 74]. If there could be any genetic defect(s) in any of the
Nos genes of the S rat causing a flaw in the L-arginine-NO
pathway, it would have to be an alteration(s) in a Nos gene(s) that
results in subtle variations in the function of the gene product(s)
either in quantity or quality, not because of a blatant lack of the
gene product(s). Thus, the challenge confronting researchers is to
unmask this naturally occurring genetic variation(s) in a Nos
gene(s) that could potentially cause hypertension in the S rat.
Then, one could not help asking the question: If the purpose is to
identify the genetic variation(s) in a Nos gene(s) that causes
hypertension, what approach would be more incisive and to the
point than the approach directly associating a Nos gene itself with
hypertension, that is, a cosegregation analysis [4]? Moreover,
because genetic variations among rat strains constitute essential
and obligatory ingredients for the cosegregation analysis, the
disadvantages imposed by genetic heterogeneity, which so se-
verely confound physiological studies, become an invaluable asset.
GENETIC ANALYSIS OF NITRIC OXIDE SYNTHASE LOCI
Linkage studies
Using F2 populations derived from crosses of inbred S rats with
various normotensive control rats, we analyzed the Nos1, Nos2
and Nos3 loci for cosegregation with blood pressure. Nos2 alleles
cosegregated significantly with blood pressure in three F2 popu-
lations, that is, in the F2 (S 3 MNS) population (P , 0.0001), in
the F2 (S 3 WKY) population (P 5 0.0070) [22], and in the F2
(S 3 LEW) population (P 5 0.0016). Table 2 presents these
results.
Nos2 alleles did not cosegregate with blood pressure in the F2
(S 3 R) population (P 5 0.61) or a backcross population, F1 (S 3
R) 3 S (P 5 0.47). Such population specificity of a cosegregation
result is common [11, 12, 17, 25], and, for Nos2, is probably due to
the presence of different alleles in each cross. S rats were
compared to R rats in the physiological studies by Chen and
Sanders [33, 50]. Physiological inferences involving the nitric
oxide system dependent on an S versus R comparison are
probably not relevant to the Nos2 locus because alleles of Nos2
did not cosegregate with blood pressure in F2 (S 3 R) or F1 (S 3
R) 3 S rats. The physiological difference in response to L-
arginine between S and R may simply be fortuitous due to genetic
drift (genetic differences unrelated to hypertension) or compen-
satory changes in response to genetic alterations in other physio-
logical systems.
The R rat has the same Nos2 allele as the S rat, but has lower
blood pressure than the S rat. This “discrepancy” can be explained
by the fact that there are numerous blood pressure QTL that
collectively control overall blood pressure of the rat strain. The
effect of high blood pressure alleles at a given QTL in the R rat
can be offset by the effects of low blood pressure alleles at the
other QTL. As presented in Table 1, on the basis of genetic
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linkage analyses, there are at least three known QTL conferring
blood pressure differences between S and R. They are marked by
Edn3, 11b-hydroxylase, and D13Mit3/R1032. To analyze the blood
pressure effect of every one of these QTL, three lines of congenic
strains were constructed independently by replacing the high
blood pressure alleles of the S rat with homologous low blood
pressure alleles of the R rat [16, 21, 26]. In other words, each
congenic strain contains the low blood pressure alleles from the R
rat at a given blood pressure QTL, such as D13Mit3/R1032, and
the rest of the genome including the two remaining QTL, such as
Edn3, and 11b-hydroxylase were homozygous for the alleles of the
S rat. Despite the presence of Nos2 alleles of the S rat, the blood
pressure for each of these congenic strain rats is significantly lower
than that of the S rat [16, 21, 26]. This fact indicates that the low
blood pressure alleles of each QTL are sufficient to “compensate”
for the effect of the high blood pressure QTL alleles at Nos2 in
each congenic strain, and they can act independently of the alleles
at the other QTL in lowering blood pressure.
In contrast to Nos2, there was no cosegregation between Nos1
alleles and blood pressure differences in four F2 populations
tested [22]. Alleles of Nos3 did not cosegregate with blood
pressure differences in F2 (S 3 LEW) (P 5 0.73), nor did it in five
other F2 populations [75]. Therefore, the “inducible” nitric oxide
synthase (Nos2) locus is a candidate for causing blood pressure
differences between the S rat and the MNS, WKY or LEW rat.
Neither the “neuronal” nitric oxide synthase (Nos1) nor the
“endothelial” nitric oxide synthase (Nos3) is a candidate.
Genetic mapping of a blood pressure quantitative trait locus on
chromosome 10 marked by Nos2
Figure 1 is adapted from Figure 1 in the article of Deng and
Rapp [22], and shows the Chromosome 10 linkage map as well as
the statistical results for the cosegregation of genetic markers of
Chromosome 10 with blood pressure in F2 (S 3 MNS). In Figure
1, numbers along the vertical line to the left of the chromosome
map are map units between loci in centiMorgan (cM) using the
Haldane correction. Orders for loci as well as distances between
loci on the chromosome map have been determined by linkage in
an appropriate F2 population using the MAPMAKER program
[76], and/or by scoring chromosome crossovers during the con-
struction of congenic strains. All markers in the region ranging
from D11MIT58 to MIT-R1704 spanning roughly 46 cM coseg-
regate strongly with blood pressure (P , 0.0001). Among these
loci, however, Nos2 exhibits the highest LOD score of 6.3 and the
highest F statistic of 15.0. (A LOD score refers to base 10
logarithm of the odds favoring linkage between a locus and its
blood pressure effect; a LOD score above 3 is considered signif-
icant.) It is likely that a blood pressure QTL is located in the
chromosome region marked by Nos2. To further reinforce this
conclusion, an independent study using an F2 (S 3 WKY)
population was performed. The results also demonstrated the
existence of a blood pressure QTL essentially localized at Nos2
[22]. Similarly, a major blood pressure QTL was localized to the
Chromosome 10 region between D10M11Mit58 and
D10M11Mit15 markers, with a maximum LOD score of 5.5 in F2
(S 3 LEW) (Fig. 2). Taken together the data from the above three
F2 populations, it appears highly likely that one, or even more
than one, blood pressure QTL exists in the Chromosome 10
region somewhere between the Mit-RR1023 and D10M11Mit84
markers (Fig. 1).
Crude physical mapping of a blood pressure quantitative trait
locus using congenic strains
A congenic strain is a strain in which a small portion of a
chromosome from one strain (the recipient) has been selectively
replaced by the homologous portion of the same chromosome of
another strain (the donor). The term homologous refers to each
pair of chromosomes that pair during meiosis. To analyze a blood
pressure QTL, it is possible to substitute two homologous chro-
mosomal fragments containing putative blood pressure-lowering
alleles of the donor strain for that containing putative blood
pressure-raising alleles of the recipient strain. If blood pressure of
the congenic strain decreases accordingly, one can conclude that
this particular chromosomal fragment harbors a QTL genetically
contributing to a difference in blood pressure between the donor
and the recipient strains.
Of the three normotensive control rat strains, that is, MNS,
WKY and LEW, the MNS strain was chosen as the donor strain
and the S strain as the recipient to produce the congenic strains of
interest in the present studies. Reasons for this choice are: (a)
markers located in the chromosome region between Ace and
D10Mit3 cosegregated highly significantly with blood pressure in
F2 (S 3 MNS) (Fig. 1). This data indicated that the probability of
donating blood pressure-lowering QTL alleles from MNS was
Table 2. Cosegregation analyses of systolic blood pressure (mean 6 SE in mm Hg) for alleles at the inducible nitric oxide synthase locus (Nos2) in
the F2 populations and a backcross population
Populations Blood pressure and genotype
One way
ANOVA (P)
WW WS SS
F2 (S 3 WKY) 164.8 6 64 (40) 175.4 6 2.58 (90) 183.3 6 4.56 (28) 0.007
MM MS SS
F2 (S 3 MNS) 165.0 6 2.34 (48) 172.3 6 2.32 (83) 187.7 6 3.48 (40) ,0.0001
LL LS SS
F2 (S 3 LEW) 179.4 6 5.53 (40) 184.4 6 3.53 (73) 205.4 6 6.35 (38) 0.0016
RR RS SS
F2 (S 3 R) 164.2 6 3.50 (33) 162.6 6 2.60 (53) 167.5 6 4.64 (26) 0.61
RS SS
F1 (S 3 R) 3 S 166.3 6 3.32 (34) 163.1 6 2.92 (36) 0.47
In the populations, S indicates Dahl salt-sensitive rat; R, Dahl salt-resistant rat; MNS, Milan normotensive rat; WKY, Wistar Kyoto rat; and LEW,
Lewis rat. Under genotypes. M represents allele for the MNS strain; R, allele for the R strain; S, allele for the S strain; W, allele for the WKY strain;
and L, the allele for the LEW strain; ANOVA, analysis of variance testing significance of differences in blood pressure among genotypes; numbers in
parentheses refer to number of rats for each genotype.
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Fig. 1. Genetic linkage map and statistical analysis in F2 (S 3 MNS) as well as congenic strains. ANOVA, one way analysis of variance for testing
the linkage of loci in F2 (S 3 MNS) to blood pressure; P indicates probability. Blood pressure difference at each locus refers to blood pressure of rats
homozygous for the MNS strain allele (MM) minus blood pressure of rats homozygous for the S strain allele (SS) in F2 (S 3 MNS). Under congenic
strains designated as a, b and c, solid vertical bars to the left of the map represent the chromosome regions of the S rat being replaced by the homologous
regions of the MNS rat. The entire regions indicated by solid bars and the junctions between the solid and open bars are homozygous MM for all the
markers listed in the corresponding positions within the solid bars on the map. Open bars at the ends of solid bars indicate that the exact breakpoints
of crossovers are unknown within an interval between markers. The junctions between the solid and open bars as well as ends of the chromosome regions
of interest in each congenic strain are connected by dotted lines to the corresponding marker positions on the map. Each thick bar graph at the bottom
left of the Figure illustrates the deviation of congenic from S rats in blood pressure for each corresponding congenic strain shown above. Abbreviations
are Ace, angiotensin-converting enzyme; Ngfr, nerve growth factor receptor, a newly developed microsatellite marker designated also as D10Mco31;
Nos2, inducible nitric oxide synthase; Syb2, synaptobrevin 2; Grm6, glutamate receptor, metabolic subtype 6; Mit-RR1023, D10Mit3 and D10Mit10 are
anonymous rat markers [77, 78]; and D10M11Mit119, D10M11Mit175 and D10M11Mit84 are anonymous mouse Chromosome 11 markers, D11Mit119,
D11Mit175 and D11Mit84, respectively, purchased from Research Genetics (Huntsville, AL, USA).
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high. (b) There were more markers mapped in F2 (S 3 MNS)
(Fig. 1) than in F2 (S 3 LEW) (Fig. 2) and F2 (S 3 WKY). This
advantage is important not only because densely-spaced markers
can minimize the chance of retaining rats with double crossovers
in a large chromosome region during construction of congenic
strains, but also they are highly valuable in the subsequent fine
mapping of a blood pressure QTL onto a smaller chromosome
region. (c) The Nos2 locus cosegregated highly significantly in F2
(S 3 MNS) (Fig. 1), but only modestly in F2 (S 3 LEW) (Fig. 2)
and in F2 (S 3 WKY) (Table 2) [22]. From the available
physiological evidence, Nos2 was an important candidate gene as
a blood pressure QTL. A congenic strain using MNS as the donor
provided an ideal test for this hypothesis.
In the present work, intended congenic strains are those
containing substitutions of chromosome regions of interest from
the S rat with the homologous regions of the MNS rat, that is,
homozygous MM for the chromosome regions in question on the
S genetic background. For this purpose, three congenic strains
have been constructed [23]. They are symbolized as congenic
strains a, b and c (Fig. 1), and are designated as S.MNS-Mit-
RR1023/Syb2, S.MNS-Mit-RR1023/D10M11Mit119, and S.MNS-
Syb2/D10M11Mit84, respectively. In designating these congenic
strains, the recipient strain S goes first, followed by a period and
the donor strain MNS. After the dash, two chromosome markers
separated by the slash indicate the chromosome region of the
recipient S strain being replaced by that of the donor MNS strain.
The chromosome region replaced in each congenic strain is
symbolized with a solid bar next to the chromosome map (left
column of Fig. 1). All the markers on the map located within the
region indicated by the solid bar are homozygous MM in all three
congenic strains. The chromosome regions shown as open bars
flanking the solid bars indicate these regions where chromosome
crossovers took place. However, due to a lack of markers inside
these regions, the breakpoints of crossovers could not be accu-
rately determined. Thus, the chromosome segment of the S rat
being replaced by that of the MNS in each congenic strain actually
includes the region indicated by the solid bar plus unknown
fragments of flanking regions inside the open bars at both ends of
each solid bar.
Since the blood pressure-lowering allele of the QTL in question
should be that of the MNS strain, which is shown as negative
numbers in the far right column in Figure 1, one would predict
that the chromosome region containing the blood pressure QTL
should have a blood pressure-lowering effect in a S.MNS congenic
strain. As diagrammatically illustrated at the bottom left corner of
Figure 1, indeed, rats of congenic strains a and b had blood
Fig. 2. Localization of a blood pressure
quantatative trait locus (QTL) in F2 (S 3
LEW). Under QTL localization, the thick bar
represents 6 1 LOD support interval, and thin
lines extending from both ends of the thick bar
indicate 6 2 LOD support interval. ANOVA is
one way analysis of variance for testing the
linkage of loci to blood pressure; P indicates
probability. Blood pressure difference at each
locus refers to blood pressure of rats
homozygous for the LEW strain allele (LL)
minus blood pressure of rats homozygous for
the S strain allele (SS) in F2 (S 3 LEW).
Abbreviations are: Ngfr, nerve growth factor
receptor; Nos2, inducible nitric oxide synthase;
Mhcg, Myosin heavy chain embryonic; Grm6,
glutamate receptor, metabolic subtype 6;
D10Mco31, a microsatellite-based marker newly
generated for Ngfr; D11Wox6, anonymous
marker provided by Dr. Mark Lathrop (Oxford
University, England, UK); D10M11Mit168,
D10M11Mit58, D10M11Mit119 and
D10M11Mit15, anonymous mouse
Chromosome 11 markers, D11Mit168,
D11Mit58, D11Mit119 and D10Mit15,
respectively, purchased from Research
Genetics.
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pressures of 42 and 35 mm Hg lower, respectively, than the
comparably raised and age-matched S strain rats. These differ-
ences with S rats are highly statistically significant (P , 0.0001).
Noticeably, both congenic strains a and b share the chromosome
region defined by Mit-RR1023 and D10M11Mit119 markers (Fig.
1), that is, this same region has been duplicated in two separate
congenic strains.
In contrast to congenic strains a and b, rats of congenic strain c,
which do not have the Mit-RR1023/D10M11Mit119 region in
common with congenic strain b (Fig. 1), had a blood pressure 9
mm Hg higher than that of the S rats. Even though this difference
of 9 mm Hg in blood pressure is marginally significant (P 5
0.016), this is the opposite of expectations (that is, blood pressure
is higher instead of lower) and too small of an effect (9 vs. 22)
compared to the results of linkage analysis (Fig. 1). Furthermore,
this difference of 9 mm Hg in blood pressure is comparable to the
difference of 7 mm Hg in blood pressure (that is, 42 minus 35),
which is not statistically significant, between congenic strains a
and b (Fig. 1). Thus, the blood pressure effect of congenic strain
c can be explained most plausibly as an artifact due to a
background noise that could arise from a substitution of any piece
of the S chromosome at random regardless of the presence of a
blood pressure QTL.
For example, a separate congenic was made by substituting a
region on Chromosome 17 of the S rat by the homologous region
of the LEW rat. In this Chromosome 17 congenic strain, the
Chromosome 10 region containing the blood pressure QTL was
homozygous for the S strain allele (SS). Similar to congenic strain
c, this Chromosome 17 congenic strain also reached blood pres-
sure 5 mm Hg higher than the S strain rats (Deng and Rapp,
unpublished observation). This result indicates that the small
blood pressure effect of 9 mm Hg for congenic strain c is likely to
be achieved by involving an arbitrary fragment from Chromosome
17 not containing a blood pressure QTL.
Recently, Kreutz et al [79] reported on a “congenic” strain
having a blood pressure effect of 6 mm Hg involving a chromo-
some segment of 6 cM in the stroke-prone spontaneously hyper-
tensive strain. Their chromosome segment falls within the chro-
mosome region between Syb2 and D10Mit3 markers, which was
included in congenic strain c (Fig. 1). It would be more informa-
tive if they had also constructed a negative control congenic strain
that would involve a piece of chromosome adjacent to, but not
overlapping, the 6 cM fragment in question.
The use of a negative control strain is especially meaningful as
a contrast to strains having positive blood pressure effects. The
negative control strain virtually eliminates the possibility that the
blood pressure effect of positive strains was due to the genetic
background incurred from residual heterozygosity in the other
part of the congenic strain genome, or due to a positional effect
[reviewed in 1]. Since the three congenic strains (a, b and c in
Figure 1) all contain largely similar genetic backgrounds in that
they diverged only in the last few generations during the congenic
constructions, the most striking differences among them are
differing lengths and regions of Chromosome 10. The negative
control strain, therefore, serves as an indicator of what effect the
genetic background has on blood pressure without the involve-
ment of the chromosome region in question that truly harbors the
blood pressure QTL in the positive congenic strains.
It has to be emphasized that the value of having a negative
control congenic strain for the positive congenic strains cannot be
Fig. 3. Ruling out of the inducible nitric oxide
synthase locus (Nos2) as a candidate blood
pressure quantitative trait locus (QTL) using a
congenic strain. Numbers to the left of
Chromosome 10 map are map units in
centiMorgans using the Haldane correction in
an F2 (S 3 MNS) population (N 5 171). The
order of loci on the map has been accurately
determined by scoring crossovers during the
construction of the congenic strain. Directly
under congenic strain d, the solid bar to the
right of the map represents the chromosome
region of the S rat being replaced by the
homologous region of the MNS rat. The open
bars at both ends of the sold bar indicate that
chromosome crossover breakpoints could not
be accurately determined within intervals
between markers. The thick bar graph at the
bottom right illustrates the blood pressure
deviation of the congenic from S rats.
Abbreviations are: Nos2 (in bold), inducible
nitric oxide synthase; Aldoc, aldolase C;
D10M11Mit119, anonymous mouse
Chromosome 11 D11Mit119 marker purchased
from Research Genetics; D10Mco1, anonymous
rat marker provided by H. Dene and O.
Dukhanina (Medical College of Ohio, Toledo,
OH, USA); D10Mgh6, anonymous rat marker
[78]; M, the MNS allele; S, the S allele.
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replaced by simply genotyping a dozen or so selected polymorphic
markers for every chromosome throughout the whole genome
(such as a total of 300 markers). For one thing, it is insufficient to
genotype a marker at, on average, every 10 to 20 cM of a
chromosome because a blood pressure QTL should be physically
under 1 cM in size. If, by any chance, a small chromosome
fragment of 1 to 2 cM in size containing a blood pressure QTL
located on another chromosome of the S rat had been unknow-
ingly replaced by the homologous fragment of the MNS rat in any
of congenic strains a, b or c presented in Figure 1, this event would
be highly likely (more than 90% of times) to be missed by
genotyping a marker at every 10 to 20 cM interval on every
chromosome. The only definitive way of making sure that the
blood pressure effect of, for example, congenic strain b shown in
Figure 1, was due to the presence of the intended fragment on
Chromosome 10, and not due to any other pieces of unknown
chromosome fragments, is to have another congenic strain (such
as congenic strain c) that contains essentially the same chromo-
somal composition throughout the genome except for the frag-
ment in question.
In conclusion, the congenic data supports the existence of a
major blood pressure QTL in the chromosome region between
Mit-RR1023 and D10M11Mit119 markers, as shown by two
positive congenic strains a and b. This conclusion is further
strengthened by a largely negative control strain c, which involved
a chromosome segment next to, yet not overlapping, the Mit-
RR1023/D10M11Mit119 region.
Test of the Nos2 locus as a candidate for the blood pressure
quantitative trait locus on Chromosome 10
On Chromosome 10, Nos2 falls into the region highly likely to
harbor a blood pressure QTL (Fig. 1). To test whether Nos2 is a
candidate blood pressure QTL, a congenic strain, designated as
congenic strain d, was constructed simultaneously with congenic
strains a, b and c (Fig. 1). Congenic strain d contained the
substitution of a chromosome fragment including Nos2 of the S
rat with the homologous fragment of the MNS rat. Figure 3 shows
the chromosome region including Nos2, and the test result for
Nos2 as the blood pressure QTL using the congenic strain [23].
If Nos2 were to be considered as a valid candidate locus for the
blood pressure QTL capable of causing a difference in blood
pressure between the S and MNS rats, rats of congenic strain d
should have blood pressure significantly lower than that of S rats.
As shown in Figure 3, blood pressure of S rats is not signifi-
cantly different from blood pressure of rats of congenic strain d
(P 5 0.18). The insignificant difference in blood pressure also
went in the opposite direction, that is, higher instead of lower than
that of S rats, as predicted from linkage analysis (Fig. 1).
Therefore, the chromosome region including Nos2 in question
does not contain a blood pressure QTL. Consequently, Nos2 itself
is not supported as a candidate QTL for causing a blood pressure
difference between the S and MNS rats.
The negative result from congenic strain d further supports the
conclusion that it is the chromosome fragment shared by the
positive congenic strains a and b (Fig. 1) where the blood pressure
QTL has to reside.
In summary, available genetic evidence does not support any
role played by a nitric oxide synthase in causing (not just being
associated with) hypertension in the S rat. The nitric oxide system,
nevertheless, seems somewhat involved secondarily in the blood
pressure regulation in the S rat, as evidenced by physiological
data.
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APPENDIX
Abbreviations used in this article are: ANP, atrial natriuretic peptide;
cM, centiMorgans; LPS, lipopolysaccharides; MNS, Milan normotensive
rat strain; NO, nitric oxide; NOS, nitric oxide synthase (enzyme); Nos,
gene or locus of nitric oxide synthase in rat or mouse; NOS, gene or locus
of nitric oxide synthase in humans; NOS1, brain nitric oxide synthase;
NOS2, inducible nitric oxide synthase; NOS3, endothelial nitric oxide
synthase; QTL, quantitative trait locus; R, Dahl salt-resistant rat strain; S,
Dahl salt-sensitive rat strain; SHR, spontaneously hypertensive rat strain;
SS, Dahl salt resistant strain allele; WKY, Wistar Kyoto rat strain.
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